Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
| ▸ | AMD1 | P17707 | 2/20 | 0.40 |
| ▸ | ADK | P55263 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18009687 | 0.89 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL31526134 | 0.85 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL21413913 | 0.81 | ADK (0.55) | PRMT5WDR77ADK | |
| SCHEMBL18009870 | 0.81 | ADK (0.55) | PRMT5WDR77ADK | |
| SCHEMBL31570701 | 0.81 | PI4KA (0.51) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL31526096 | 0.80 | PI4KA (0.49) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL18026301 | 0.77 | PRMT5 (0.45) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL18009671 | 0.77 | PRMT5 (0.45) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL18572295 | 0.75 | PRMT5 (0.59) | PRMT5WDR77 | |
| SCHEMBL18026298 | 0.75 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262057-B1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3262057-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135582-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | PI4KA 769/4885PI4K2B 1095/4885PI4K2A 903/4885 |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | PI4KA 989/4885PI4K2B 1184/4885PI4K2A 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.